The price of vosoritide, the market reference cost for different courses of treatment and the description of the drug purchase plan

Vosoritide is a targeted growth factor drug used to treat achondroplasia (achondroplasia) in children. It can promote long bone growth by selectively activating receptor signaling. At present, the drug has not yet been launched in China, so domestic patients cannot obtain it directly through hospital pharmacies, and there is no domestic medical insurance or reimbursement channel. If patients wish to use vosolitide, they need to pay attention to overseas drug purchase or clinical trial opportunities.

In overseas markets, the price of the original drug of vosolitide is relatively high. Taking the European market as an example, the cost of each course of treatment for a standard dose of vorsolitide is approximately 6.9 RMB. This cost is usually the total price calculated on an annual or monthly basis. Medication dosages may vary among children of different ages and weights, so actual medication costs will be adjusted based on the child's weight, treatment duration, and dosing frequency.

Vorsolitide is usually administered as a once-daily subcutaneous injection, with the dose calculated based on body weight. Clinical guidelines recommend regular monitoring of growth rate, bone age, and related laboratory indicators to evaluate efficacy and adjust dosage. For patients who purchase drugs overseas, they usually need to complete a long-term medication plan through authorized import channels or overseas pharmacies in conjunction with doctor's guidance to ensure dosage accuracy and safety.

In general, vorsolitide is currently not available for direct purchase in China. Its high overseas price and long-term medication requirements mean that patients and families need to fully understand the drug purchase channels, costs and follow-up arrangements. As drugs are promoted in the global market and may be launched domestically in the future, drug access channels and cost references are expected to become clearer, providing patients with more convenient treatment options and long-term management plans.

Reference materials:https://www.drugs.com/